Nymox Pharmaceutical Corp (NASDAQ:NYMX)

4.19
Delayed Data
As of Apr 20
 +0.01 / +0.24%
Today’s Change
3.00
Today|||52-Week Range
5.10
+26.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$188.1M

Company Description

Nymox Pharmaceutical Corp.operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Contact Information

Nymox Pharmaceutical Corp.
Bay & Deveaux Streets
Nassau New Providence --
P:(800) 936-9669
Investor Relations:

Employees

Shareholders

Individual stakeholders5.78%
Other institutional3.71%
Mutual fund holders2.82%

Top Executives

Paul AverbackChairman, President & Chief Executive Officer
Erik DanielsenChief Financial Officer
Randall LanhamSecretary, Director & General Counsel